Filing Flows › Arcus Biosciences (RCUS) › Q3 2026
Arcus Biosciences (RCUS) Q3 2026 earnings results (third quarter 2026)
10-Q filed Nov 4, 2026
Arcus Biosciences (RCUS) reported revenue of $9.0M for the third quarter 2026 (Q3 2026), -65% from a year earlier and -78% from the quarter before.
Arcus Biosciences, Q3 2026: revenue $9.0M (-65% year over year), net loss $128M, operating cash flow −$88.0M. The chart follows the revenue to costs, profit and cash.
| Q3 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $9.0M | -78% | -65% |
| Operating profit | −$131M | — | — |
| Net earnings | −$128M | — | — |
| Operating cash flow | −$88.0M | — | — |
What changed
Revenue was $9.0M in Q3 2026, down 65% year over year and down 78% from the previous quarter. License and development services was the largest line at 89% of revenue. License and development services lost $12.0M year over year (down 60%), 71% of the total change.
Operating costs exceeded revenue by $131.0M, an operating margin of -1455.6%. Total costs fell 17% while revenue fell 65%. The quarter ended with a net loss of $128.0M, wider than the previous quarter's $91.0M loss.
Operating cash flow was −$88.0M. Non-cash charges added back $2.0M of depreciation and amortization and $16.0M of share-based compensation. Working capital and other items added $22.0M.
Questions
What was Arcus Biosciences' revenue in the third quarter 2026?
Arcus Biosciences (RCUS) reported revenue of $9.0M for the third quarter 2026 (Q3 2026), -65% from a year earlier and -78% from the quarter before.
Source: Arcus Biosciences 10-Q on SEC EDGAR.